quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:15:00·154d
PRRelease
Exact Sciences Corporation logo
IDEAYA Biosciences Inc. logo
Illumina Inc. logo
+7

Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

EXAS· Exact Sciences CorporationIDYA· IDEAYA Biosciences Inc.ILMN· Illumina Inc.IR· Ingersoll Rand Inc.LIFE· Ethos Technologies Inc.MTD· Mettler-Toledo International Inc.
Health CareIndustrialsFinance
Original source

Companies

  • EXAS
    Exact Sciences Corporation
    Health Care
  • IDYA
    IDEAYA Biosciences Inc.
    Health Care
  • ILMN
    Illumina Inc.
    Health Care
  • IR
    Ingersoll Rand Inc.
    Industrials
  • LIFE
    Ethos Technologies Inc.
    Finance
  • MTD
    Mettler-Toledo International Inc.
    Industrials
  • QTRX
    Quanterix Corporation
    Industrials
  • SERA
    Sera Prognostics Inc.
    Health Care
  • TMO
    Thermo Fisher Scientific Inc
    Industrials
  • TROW
    T. Rowe Price Group Inc.
    Finance

Recent analyst ratings

  • Mar 27TMOUpdateDZ Bank$610.00
  • Mar 20MTDUpdateJefferies$1,450
  • Feb 23LIFEUpdateGoldman$33.00
  • Feb 23LIFEUpdateRobert W. Baird$18.00
  • Feb 23LIFEUpdateCitizens$21.00
  • Feb 23LIFEUpdateBarclays$20.00

Related

  • PR7h
    Ingersoll Rand Declares Regular Quarterly Cash Dividend
  • PR14h
    Ethos Collaborates with Liberty Mutual to Deliver a Modern, Digital-First Life Insurance Experience
  • SEC17h
    Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR17h
    Thermo Fisher Scientific Reports First Quarter 2026 Results
  • PR1d
    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026
  • SEC1d
    T. Rowe Price Group Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • SEC2d
    SEC Form 144 filed by Sera Prognostics Inc.
  • PR2d
    IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022